BioAtla is laying off 30% of staff as the biotech searches for partners for some of its conditionally active biologic (CAB) ...

From April 25 to 30, 2025, the American Association for Cancer Research (AACR) Annual Meeting will take place in Chicago. CStone will showcase its latest preclinical studies on five internally ...

The global bispecific antibody (BsAb) market has witnessed significant growth, with 17 bispecific antibody therapies already ...

Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial ...

Reports revenue $103,204 vs. $18.1M last year. “The clinical data we generated in 2024 with ADG126 gives us great confidence in our ability to ...

On February 28, Amgen, Inc. (“Amgen”) filed three petitions for inter partes review, challenging the validity of all claims in three patents assigned to Bristol-Myers Squibb Co. (“BMS”).

CStone Pharmaceuticals has dosed the first subject in the multicentre Phase I trial of its trispecific antibody, CS2009.

Key Findings: In the proof of mechanism studies, CS2009 demonstrated strong synergy between the PD-1 and CTLA-4 arms, and the checkpoint inhibitory activity from the PD-1/CTLA4 arms was also greatly ...